Grafton, WI -- February 13, 2007 -- Cedarburg Pharmaceuticals, Inc., a drug process development and API provider, today announced that it has raised a total of $3.5 million in the company's Series A-3 (fourth round) of preferred stock financing.   Read the full press release >

Cedarburg Pharmaceuticals welcomes contact from members of the press. For answers to specific questions, help researching a technology or industry-related topic, or to set up an interview with a Cedarburg spokesperson, please contact:

Ken Li
312-375-1157
kli@chempetitive.com